MedTrace Logo

Effect of Antidepressants on White Matter Structure

NCT01492621 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-12-15

No results posted yet for this study

Summary

Subjects with major depression will be evaluated and intensively characterized through questionnaires, computerized cognitive evaluation and laboratory investigations. Magnetic resonance imaging will be used to document baseline white matter structure. subjects will then receive desvenlafaxine which will be adjusted as clinically indicated. After 16 weeks the evaluations will be repeated.

Conditions

Interventions

DRUG

Desvenlafaxine

Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal

    lead OTHER

Principal Investigators

  • Smadar V Tourjman, MDCM · University of Montreal, Centre de recherche Fernand Seguin

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-09-30
Completion
2013-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01492621 on ClinicalTrials.gov